Prakiraan pendapatan perusahaan: OS Therapies Inc (OSTX)

Lambang korporat lan logo OS Therapies Inc. (OSTX)

OS Therapies Incorporated (OSTX) is developing a portfolio of osteosarcoma drugs, seeking partnerships with industry behemoths. The business model relies on patents, which will ensure high margins through outsourced production. The company's sales volume forecasts confirm market expectations, where the latest parameter is 0.00. The issuer's success depends on drug test results and obtaining orphan drug status.

ostherapies.com - Pendapatan mangsa ngarep perusahaan OSTX (periode 02.08.2024 - 16.11.2026)

Rincian metrik keuangan lan pasar OS Therapies Inc (OSTX)

- nilai saham lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:OSTX OS Therapies
Produk merek OS Therapies Inc.

The development of immunotherapy for the treatment of osteosarcoma drives the revenue expectations for OS Therapies Incorporated (OSTX). This indicator reflects the market capitalization of the issuer's rights to future cash flows. The calculation is based on the discounting of projected vaccine sales revenues through insurance funds. The growth of this metric confirms investor confidence in the commercial success of the drugs, allowing speculative noise to be separated from the actual fundamental trend.

Pesaing langsung

Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan pendapatan perusahaan ymabs.com (YMAB)|Prakiraan pendapatan perusahaan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Volume dodolan mangsa ngarep perusahaan|Accuray Inc. (ARAY) - Volume dodolan sing dikarepake perusahaan|SELLAS Life Sciences Group, Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Prakiraan pendapatan perusahaan|HURA - Dodolan mangsa ngarep perusahaan|TARA (Protara Therapeutics, Inc.) - Prakiraan volume dodolan|Prakiraan volume dodolan Fate Therapeutics Inc|Prakiraan volume dodolan WHWK|Prakiraan volume dodolan TScan Therapeutics Inc (TCRX)|Prakiraan pendapatan perusahaan championsoncology.com CSBR|XBIT - Volume dodolan mangsa ngarep perusahaan|CVM - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan RADX (Radiopharm Theranostics)|Artiva (ARTV) - Prakiraan pendapatan perusahaan|ANL: Prakiraan volume pendapatan perusahaan|VERU (Veru Corporation) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Tempest Therapeutics, Inc. TPST|Prakiraan volume dodolan XLO|Renovaro - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Mural Bio MURA|KAPA: Prakiraan pendapatan perusahaan|OnKure Therapeutics - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan w2.cytomed.sg GDTC|CRIS: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Apollomics Inc.|THAR (Tharimmune Corporation) - Prakiraan volume dodolan|Prakiraan volume dodolan Advanced Biomed Inc|Prakiraan volume dodolan GNPX|Volume dodolan mangsa ngarep perusahaan Calidi Biotherapeutics Inc. CLDI|Prakiraan pendapatan perusahaan Sunshine Biopharma Inc. SBFM|Dodolan mangsa ngarep perusahaan Xenetic Biosciences (XBIO)|SLRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Kitov Pharma|AON (AONC) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan